Investments In Health And Emerging Markets Will Unlock Long-Term Value

Key Takeaways

• Strategic divestitures and R&D investments are sharpening focus on higher-margin, innovative products, expected to boost future growth and earnings quality.
  
• Expansion in emerging markets and rising demand for health-conscious products position the company for sustained revenue growth and premium pricing.
  
• Softness in key markets, product commoditization, and reliance on innovation threaten profitability, while capital intensity and local competition could limit growth and margin expansion.

Catalysts

Manufactures and markets food, beverage, health and biosciences, scent, pharma solutions, and complementary adjacent products in the United States, Europe, and internationally.

• Recent divestitures of commodity businesses (e.g., Pharma Solutions, Soy Crush, Concentrates, Lecithin) and the ongoing strategic evaluation of the Food Ingredients segment are increasing IFF's focus on differentiated, higher-margin, innovation-driven products-supporting future margin expansion and higher earnings quality.
  
• Ongoing investments in R&D and capacity (especially in Health & Biosciences, Taste, and Specialty Fragrance Ingredients) are strengthening the company's innovation pipeline; management expects these initiatives to accelerate revenue and profit growth beginning in 2026 and reaching full impact by 2027.
  
• IFF is positioned to benefit from rising consumer demand for clean-label, health-focused, and better-for-you products-trends that are accelerating globally with regulatory support (such as sugar/salt/fat reduction labeling in both developed and emerging markets), which is expected to drive higher volume growth and support premium pricing.
  
• Proactive expansion and renewed focus in high-growth emerging markets-most notably Latin America, EMEA, and Asia-are expected to capture increased consumption as urbanization, middle class growth, and shifting dietary patterns fuel demand for value-added food and personal care ingredients, acting as a tailwind for long-term revenue growth.
  
• The company's significant deleveraging and strengthened balance sheet (now at 2.5x net debt/EBITDA after divestitures) have restored financial flexibility, enabling increased reinvestment in core businesses and disciplined capital returns (dividends, share buybacks), supporting a sustainable long-term EPS growth profile.

International Flavors & Fragrances Future Earnings and Revenue Growth

Assumptions

• Analysts are assuming International Flavors & Fragrances's revenue will decrease by 0.3% annually over the next 3 years.
• Analysts assume that profit margins will increase from -3.5% today to 6.9% in 3 years time.
• Analysts expect earnings to reach $784.4 million (and earnings per share of $3.23) by about August 2028, up from $-393.0 million today. However, there is some disagreement amongst the analysts with the more bullish ones expecting earnings as high as $864 million.
• In order for the above numbers to justify the analysts price target, the company would need to trade at a PE ratio of 35.0x on those 2028 earnings, up from -43.4x today. This future PE is greater than the current PE for the US Chemicals industry at 25.5x.
• Analysts expect the number of shares outstanding to grow by 0.25% per year for the next 3 years.
• To value all of this in today's terms, we will use a discount rate of 8.07%, as per the Simply Wall St company report.

International Flavors & Fragrances Future Earnings Per Share Growth

Risks

• Ongoing softness in key markets such as North America and China, along with specifically weak performance in the Health segment of Health & Biosciences, may cause negative growth and drag revenue and net margins in the near to medium term.
  
• The Fragrance Ingredients business is experiencing sustained downturns due to low-cost competition and commoditization, with continued volume and pricing pressures expected to persist until at least 2026, which could erode overall profitability and compress margins.
  
• The company's reliance on successful innovation and R&D pipeline improvements-especially in probiotics and specialty ingredients-creates a risk if these new products do not reach commercialization or fail to offset declining legacy businesses, potentially slowing long-term revenue growth and adversely affecting earnings.
  
• Food Ingredients, despite margin improvement efforts, remains more capital intensive with potential stranded costs and operational complexity arising from ongoing divestitures or a future sale; failure to fully resolve these issues could constrain free cash flow and reduce net income.
  
• Increasing challenges from rapidly innovating local competitors and slower growth in developed markets may limit IFF's ability to consistently outperform the market, reducing pricing power and pressuring both top-line growth and future margin expansion.

Valuation

• The analysts have a consensus price target of $84.253 for International Flavors & Fragrances based on their expectations of its future earnings growth, profit margins and other risk factors. However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $105.0, and the most bearish reporting a price target of just $68.0.
• In order for you to agree with the analyst's consensus, you'd need to believe that by 2028, revenues will be $11.4 billion, earnings will come to $784.4 million, and it would be trading on a PE ratio of 35.0x, assuming you use a discount rate of 8.1%.
• Given the current share price of $66.51, the analyst price target of $84.25 is 21.1% higher.
• We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.